Crossmark

Evaluation of Pafolacianine (Cytalux®) for Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma: A Negative Study with Important Clinical Implications

Crossref DOI link: https://doi.org/10.1007/s11307-025-02068-3

Published Online: 2025-12-11

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mani, Lucas

Zaidi, Syeda Maria Ahmad

Martin, Estelle

Burns, Carleigh Rose

Naveed, Abdullah Bin

McAdoo, Ashtyn

Tanaka, Hidenori

Rosenthal, Eben

Hom, Marisa
License Information

Text and Data Mining valid from 2025-12-11

Version of Record valid from 2025-12-11
More Information

Article History

Received: 8 August 2025

Revised: 9 October 2025

Accepted: 11 November 2025

First Online: 11 December 2025

Declarations

:

: The authors declare no conflicts of interest related to this work. Pafolacianine was provided by On Target Laboratories for investigational use without financial compensation or obligations.

Document is current

Any future updates will be listed below